Detailed price information for Astrazeneca Plc Ord (AZNCF) from The Globe and Mail including charting and trades.

The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...

Akums Drugs and Pharmaceuticals Ltd., India's largest contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter ended June 30, 2025.

The BSE Sensex surged 746 points (0.93%) to close at 80,604.08 on Monday, driven by strong buying in oil, auto, and banking stocks, alongside fresh foreign fund inflows.

The findings suggest that patients with type 2 diabetes treated with GLP-1 agonists require regular screening and monitoring ...

Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.

Q: I have Type 2 diabetes, and my doctor insists that I give up beverages with almost all sugar substitutes and stick with water. Can you explain what’s wrong with ...

In August 2025, Bayer announced a study of researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the ...

AstraZeneca's Farxiga (dapagliflozin) for diabetes, heart failure, and chronic kidney disease – down 68% to $178.50; Immunex's Enbrel (aflibercept) for rheumatoid arthritis, psoriasis, and ...